共 50 条
- [21] The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation plus /- Surgery for Stage III EGFR-Mutant NSCLCJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S188 - S188Piper-Vallillo, A.Mak, R.Lanuti, M.Muzikansky, A.Rotow, J.Janne, P.Mino-Kenudson, M.Swanson, S.Wright, C.Kozono, D.Marcoux, J.Piotrowska, Z.Willers, H.Sequist, L.
- [22] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 1030 - 1041Aredo, Jacqueline V.Mambetsariev, IsaHellyer, Jessica A.Amini, AryaNeal, Joel W.Padda, Sukhmani K.McCoach, Caroline E.Riess, Jonathan W.Cabebe, Elwyn C.Naidoo, JarushkaAbuali, TariqSalgia, RaviLoo Jr, Billy W.Diehn, MaximilianHan, Summer S.Wakelee, Heather A.
- [23] Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiationCANCER RESEARCH, 2023, 83 (07)Yeo, Chang DongKang, Hye SeonKim, In KyoungLee, Sang HaakKim, Jin Woo
- [24] Identification of predictive factors for early relapse in patients with unresectable stage III NSCLC receiving consolidation durvalumab after concurrent chemoradiationRESPIROLOGY, 2023, 28 : 98 - 98Nam, Jung HyunYeo, Chang DongPark, Chan KwonKim, Sung KyoungKim, Ju SangKim, Yong HyunKim, Jin WooKim, Seung JoonLee, Sang HakKang, Hye Seon
- [25] Pulmonary toxicities after chemoradiation followed by durvalumab for stage III NSCLC: a real settingRADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1069 - S1070Nicolet, C.Briot, N.Amoyal, C.Chevalier, C.Jeandidier, C.Kaderbhai, C.Foucher, P.Westeel, V.Martin, E.
- [26] PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLCANTICANCER RESEARCH, 2024, 44 (10) : 4505 - 4516Kim, InsuChoi, Sun HaLee, Shin YupYoo, Seung SooPark, Ji EunShin, Kyeong-CheolJang, Jong GeolHong, Kyung SooKwon, Yong ShikPark, Sun HyoChoi, Keum-JuJung, Chi YoungKim, Mi-HyunKim, Soo HanSeol, Hee YunKim, JehunPark, Jin-HanKim, Tae HoonEom, Jung SeopAhn, June Hong
- [27] Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutationANNALS OF ONCOLOGY, 2023, 34 : S1649 - S1649Wu, L.Jia, H. R.
- [28] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLCANNALS OF ONCOLOGY, 2021, 32 : S941 - S941Kian, W.Roisman, L. C.Dudnik, J.Chernomordikov, L.Allen, A. M.Corn, B.Dudnik, E.Rosenberg, S. K.Zemel, M.Lavrenkov, K.Peled, N.
- [29] Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCJOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 109 - 118Nassar, Amin H.Jayakrishnan, RitujithFeng, JamieShepherd, FrancesAdib, ElioCheung, Justin M.Lin, Jessica J.Liu, YufeiLin, Steven H.Parikh, KaushalSridhar, ArthiShakya, PurnimaDilling, Thomas J.Kaldas, DavidGray, Jhanelle E.Lobachov, AnastasiyaBar, JairLuders, HeikeGrohe, ChristianGupta, ShrutiLeal, TicianaFitzgerald, BaileyCrowley, FionnualaFujiwara, YuMarron, Thomas U.Wilgucki, MollyReuss, JoshuaChen, LuxiSankar, KamyaAredo, Jacqueline, VNeal, Joel W.Wakelee, Heather A.Thummalapalli, RohitYu, HelenaWhitaker, RyanVelazquez, AnaRagavan, MeeraCortellini, AlessioKwiatkowski, David J.Naqash, Abdul RafehGoldberg, Sarah B.Kim, So Yeon
- [30] Durvalumab Approved for Unresectable Stage 3 NSCLC After ChemoradiationCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 273 - 273Schuyler, Devon